Ridgeline Therapeutics

Ridgeline Therapeutics is a private, preclinical-stage biotech pioneering a novel therapeutic approach by inhibiting the NNMT enzyme. The company's platform aims to address multiple major chronic diseases linked to dysregulated cellular metabolism and epigenetic pathways through once-daily oral drugs. Led by a scientifically experienced founding team and supported by a seasoned business advisory board, Ridgeline is advancing its lead candidates toward clinical development in large, underserved markets.

Discovery and development of highly selective small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) to modulate cellular energy metabolism and epigenetic pathways.

While NNMT is a novel target with few known direct competitors, Ridgeline competes indirectly in large markets dominated by established drug classes (e.g., GLP-1s for diabetes/obesity) and companies developing therapies for muscle wasting and dystrophies. Its success depends on demonstrating superior or complementary efficacy/safety.